ClinicalTrials.gg
RecruitingNCT06030830SMaRTUpdated Sep 11, 2023

SMaRT Mom - Smartphone Management and Responsive Time for Breastfeeding Mothers

An interventional study of SMaRT Mom in Smartphone Addiction, Breastfeeding and Infant Behavior, sponsored by Bar-Ilan University, Israel. Recruiting at 1 site in Israel. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Bar-Ilan University, Israel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

In the last decade, infants are born into a social environment in which the smartphone has become an essential part of our lives. Smartphone use draws the mother's attention during mother-infant interactions and thus may affect the infant development as well as maternal self-efficacy. However, the effects of smartphone use reduction among breastfeeding mothers during their interactions with their infants have not been studied yet. In the present study, we propose to evaluate a "SMaRT Mom" intervention that we have developed, to manage and reduce smartphone use during breastfeeding. The purpose of the study is to evaluate the effects of the SMaRT Mom intervention on breastfeeding mothers' biobehavioral mechanisms, self-efficacy and the socioemotional characteristics of their infants. This will extend our knowledge of the peculiarities of early mother-infant interactions in the digital era, when smartphones play a critical role.

02

Conditions studied

  • Smartphone Addiction
  • Breastfeeding
  • Infant Behavior
  • Mother-Infant Interaction

Keywords

  • Smartphone addiction
  • Problematic smartphone use
  • Breastfeeding
  • Infant temperament
  • Mother-infant interaction
03

In context

Internet Addiction Disorder

167 studies on the registry are indexed under Internet Addiction Disorder; 45 are open to participants now.

This study's planned enrollment of 100 is above the median of 88 across 96 interventional studies indexed under Internet Addiction Disorder.

Browse Internet Addiction Disorder studies →

Lead sponsor

Bar-Ilan University, Israel is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3-6 months old infant
  • Smartphone Addiction Scale' cut-off (31 and above)

Exclusion criteria

Exclusion Criteria:

  • No neurological disorders
  • No heart disease
  • No anxiety and depression
  • No use of psychiatric drugs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will be instructed not to use the smartphone during breastfeeding for a week

    Behavioral: SMaRT Mom

  • No intervention
    Control

    Participants will not be instructed not to use the smartphone during breastfeeding for a week

Interventions

  • BehavioralSMaRT Mom

    "SMaRT Mom" intervention that we have developed is based on several approaches to digital addiction detection, prevention, and intervention aimed to help breastfeeding mothers to manage and reduce smartphone use during breastfeeding. The SMaRT Mom intervention results will be measured in changes in two main outcomes: 1) reduced maternal reports of their infants' negative emotionality, and 2) increased maternal self-efficacy as distal outcomes as well as two proximal outcomes: 1) breastfeeding as a rewarding experience, and 2) maternal attention towards their infant during breastfeeding. We will then assess changes in breastfeeding mothers' neural activity, physiology and behavior before and after the implementation of the SMaRT Mom intervention, as potential mechanisms underlying changes in the main outcomes of the intervention.

06

What researchers measure

Primary outcomes

  1. Infant temperament

    Infants' temperament will be reported by breastfeeding mothers before and after the intervention week using the Infant Behavior Questionnaire - Revised - Very Short Form (IBQ-rvsf). Scale scores represent the mean score of all scale items applicable to the child, as judged by the caregiver. 1. Sum all numerical item responses for a given scale. Note that: a) If caregiver omitted an item, that item receives no numerical score; b) If caregiver checked the "does not apply" response option for an item, that item receives no numerical score; 2. Divide the total by the number of items receiving a numerical response. Not including items marked "does not apply (N/A)" or items receiving no response in determining the number of items. The surgency, negative affect and effortful control subscales' items will be averaged

    Time frame: Pre (day 1) and post (day 8) lab visit (before and after intervention/control week)

  2. Maternal self-efficacy

    Maternal self-efficacy questionnaire (MSQ) will be self-reported by breastfeeding mothers before and after the intervention week. The scale applies a special method to measure maternal self-efficacy and mostly focuses on a mother's infant care responsibilities. The scale consists of 10 items.Higher score indicates higher maternal self-efficacy

    Time frame: Pre (day 1) and post (day 8) lab visit (before and after intervention/control week)

Secondary outcomes

  1. Breastfeeding as a rewarding experience

    The rewarding experience of breastfeeding will be self-reported by mothers before and after the intervention week ("How rewarding is the experience of breastfeeding for you?")

    Time frame: Pre (day 1) and post (day 8, day 14, day 30) lab visit after intervention/control week

  2. Self-reported maternal attention towards infant

    Maternal attention towards the infant will be self-reported by mothers before and after the intervention week ("How attentive do you feel towards your infant during breastfeeding?")

    Time frame: Pre (day 1) and post (day 8, day 14, day 30) lab visit after intervention/control week

  3. Video recorded maternal attention towards infant

    Maternal attention towards the infant will be video recorded during both laboratory sessions

    Time frame: day 1 and day 8 during lab visits

  4. Changes in breastfeeding mothers' neural activity - Frontal asymmetry

    Frontal asymmetry during maternal baseline, breastfeeding and mother-infant face-to-face interaction EEG data will be acquired from breastfeeding mothers' heads using Enobio8 device with eight electrodes from the frontal, and central-parietal areas - Fp1, Fp2, F3, F4, F7, F8, P3 and P4 and voltage fluctuations in the alpha frequency band will be measured between pairs of electrodes that will be produced by the excitation of neuronal synapses.

    Time frame: day 1 and day 8 during lab visits

  5. Changes in breastfeeding mothers' neural activity - ERP

    Event related response during the smartphone cue-reactivity task, attentional bias is indicated by an enhancement in the late positive potential (LPP), which is strongly evoked by emotionally salient stimuli. The LPP is maximum over central-parietal regions occurring between 300 and 700 ms following an emotional stimulus

    Time frame: day 1 and day 8 during lab visits

  6. Changes in breastfeeding mothers' physiological responses - HRV

    Heart Rate Variability (HRV) will be measured via The MindWare Mobile Recorder (MindWare Technologies, Inc., Gahanna, OH), a well-validated and specialized hardware and software system that is aimed at monitoring autonomic balance, cardiac performance, respiratory measurements and activity. Participants are each will be fitted with a MindWare Mobile device and specialized electrodes to measure the electrocardiogram (allows to derive HRV), Z0, dz/dt (allows to assess respiration and cardiology impedance) and SCL (allows to derive electrodermal activity from the skin) (for similar method see Nomkin \& Gordon, 2021).

    Time frame: day 1 and day 8 during lab visits

  7. Changes in breastfeeding mothers' physiological responses - Electrodermal activity

    Skin Conductance Level (SCL) will be measured via The MindWare Mobile Recorder (MindWare Technologies, Inc., Gahanna, OH), a well-validated and specialized hardware and software system that is aimed at monitoring autonomic balance, cardiac performance, respiratory measurements and activity. Participants are each will be fitted with a MindWare Mobile device and specialized electrodes to measure the electrocardiogram (allows to derive HRV), Z0, dz/dt (allows to assess respiration and cardiology impedance) and SCL (allows to derive electrodermal activity from the skin) (for similar method see Nomkin \& Gordon, 2021).

    Time frame: day 1 and day 8 during lab visits

  8. Changes in breastfeeding mothers' physiological responses - Cardiograph Impedance

    Cardiograph Impedance will be measured via The MindWare Mobile Recorder (MindWare Technologies, Inc., Gahanna, OH), a well-validated and specialized hardware and software system that is aimed at monitoring autonomic balance, cardiac performance, respiratory measurements and activity. Participants are each will be fitted with a MindWare Mobile device and specialized electrodes to measure the electrocardiogram (allows to derive HRV), Z0, dz/dt (allows to assess respiration and cardiology impedance) and SCL (allows to derive electrodermal activity from the skin) (for similar method see Nomkin \& Gordon, 2021).

    Time frame: day 1 and day 8 during lab visits

07

Study locations

1 of 1 sites recruiting
  • Gonda Brain Center, Bar-Ilan University
    Ramat Gan, Israel
    Recruiting
    • Ilanit Gordon, Prof. · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jul 2025, 25 months after the start.

Of 73 non-industry interventional studies with no phase under Internet Addiction Disorder, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 10. This study's planned 25 months is above that.

Counting every sponsor, half of 73 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2023
First posted
Sep 11, 2023
StartActual
Jun 6, 2023
Primary completionEst.
Jul 2025
CompletionEst.
Oct 2025
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06030830
Lead sponsor
Bar-Ilan University, Israel
Responsible party
Prof. Ilanit gordon (prof., Bar-Ilan University, Israel) — Principal investigator
First posted
Sep 11, 2023
Start date
Jun 6, 2023
Primary completion
Jul 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
Sep 11, 2023

Study contacts

Ilanit Gordon, Prof.
Contact
ilanit.gordon@biu.ac.il
+972 - 3-5317520
Lilach Graff Nomkin, PhD student
Contact
lgnomkin@gmail.com
: +972545445013
Ilanit Gordon, Prof.
study chair · Department of Psychology, Gonda Brain Research Center Bar-Ilan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion